Trigonelline: The Next-Gen NAD+ Precursor, Reviewed

Trigonelline is the newest name in the NAD+ conversation — a naturally occurring alkaloid found in coffee, fenugreek seeds, and other plants that, in 2024, was formally identified as a previously overlooked precursor to NAD+. For a field dominated by NMN and NR, that's a genuinely interesting development, and the search interest has followed. But "newly discovered precursor" is exactly the kind of phrase that gets ahead of the evidence. This page lays out what trigonelline actually is, what the landmark research really demonstrated, and — just as importantly — what it has not yet shown in healthy humans buying it as a supplement.

The honest summary up front: trigonelline has a real, peer-reviewed mechanism connecting it to NAD+ and a striking 2024 study in muscle ageing — but its human-outcome evidence is early, narrow, and not the broad "anti-aging" validation the supplement marketing implies.

What trigonelline is

Trigonelline (N-methylnicotinic acid) is a plant alkaloid — a methylated form of niacin (vitamin B3). It's one of the most abundant bioactive compounds in coffee, which is the main dietary source for most people, and it's also concentrated in fenugreek seeds. Chemically it sits in the same vitamin-B3 family as the better-known NAD+ precursors, which is the structural clue behind its newly recognized role: like nicotinic acid and nicotinamide, it can feed into the cellular pathways that build NAD+ ¹.

NAD+ (nicotinamide adenine dinucleotide) is the coenzyme at the center of cellular energy metabolism and the fuel for DNA-repair enzymes and the sirtuins — and its decline with age is the entire rationale behind the precursor supplement category. We cover that whole landscape in our NAD+ therapy evidence pillar. The question for trigonelline is whether it does that job — raising NAD+ and translating into benefit — any better than the precursors that came before it.

The landmark finding: trigonelline as an NAD+ precursor

The reason trigonelline is being discussed at all comes from a single, high-profile 2024 study published in Nature Metabolism by Membrez and colleagues ². This is the keystone paper, and it's worth being precise about what it actually demonstrated.

The researchers reported three connected things. First, trigonelline levels were lower in people with sarcopenia (age-related muscle loss), and lower trigonelline correlated with worse muscle strength and mitochondrial function — an association in humans. Second, in cells and model organisms, trigonelline was shown to be metabolized into NAD+, raising intracellular NAD+ and improving mitochondrial activity. Third, in aged mice and in C. elegans worms, supplementing trigonelline increased NAD+ and improved muscle function and strength ². Together, that's a coherent, mechanistically grounded story: a dietary compound that the body can convert to NAD+, that's depleted in age-related muscle decline, and that restores muscle function in animals.

That's a legitimately important result, and it earns trigonelline its place in the precursor conversation. But notice the structure of the evidence: the human data is observational (people with sarcopenia have less trigonelline), while the interventional data — actually giving trigonelline and seeing muscle improve — is in cells, worms, and mice, not in a human treatment trial. That distinction is the whole ballgame for a supplement buyer.

What the evidence does NOT yet show

Here is the part the marketing glides past. As of now, there is no published randomized controlled trial showing that supplementing trigonelline raises NAD+ or improves muscle, energy, or aging outcomes in healthy humans. The compelling muscle-restoration data is preclinical ²; the human side of the keystone study is a correlation, not a treatment result.

This matters because we have already watched this exact gap play out with the established precursors — and the lesson is humbling. Oral NMN and NR reliably raise blood NAD+ in human trials ³⁴, yet raising the biomarker has repeatedly failed to translate into how people feel or perform: a randomized NMN trial confirmed the NAD+ rise without dramatic functional payoff ³, the clearest positive human signal is narrow (improved muscle insulin sensitivity in prediabetic women) ⁵, and a systematic review and meta-analysis found the metabolic benefits of NAD+ precursors limited and inconsistent despite reliably raised NAD+ ⁶. If the precursors with human RCTs struggle to convert higher NAD+ into benefit, a precursor whose human evidence is still observational cannot honestly claim to have cleared that bar. We walk through that recurring "biomarker up, outcome flat" pattern in detail in does NMN actually work?.

Beyond the keystone paper, the broader trigonelline literature is mostly mechanistic and preclinical. Review articles catalog a wide range of potential pharmacological activities — anti-diabetic, neuroprotective, anti-inflammatory effects seen largely in cell and animal models — while noting the evidence base in humans remains thin ¹⁷. That's the standard profile of an early-stage bioactive: promising signals across many directions, few of them yet confirmed in controlled human trials.

Trigonelline vs NMN and NR

It's natural to ask how trigonelline stacks up against the incumbents. The honest comparison isn't flattering to the newcomer's marketing:

• •NMN and NR have multiple human trials proving they raise blood NAD+, plus dedicated safety studies — though their downstream benefits remain modest and mixed ³⁴⁶. We compare those two head-to-head in NMN vs NR.
• •Trigonelline has a strong mechanism and a landmark preclinical-plus-observational study ², but no human supplementation trial yet. Its evidence is newer and thinner, not stronger.

So anyone framing trigonelline as a "superior" or "next-generation" NAD+ booster is selling a hypothesis, not a demonstrated result. Its real distinction is that it's a naturally dietary precursor (you already consume it in coffee) with an intriguing tie to muscle ageing — not that it has out-competed NMN or NR on proof.

Safety, dosing, and the supplement reality

Because trigonelline is consumed daily by billions of coffee drinkers in milligram quantities with a long history of dietary exposure, the raw compound isn't exotic. But that everyday-coffee safety record does not automatically extend to concentrated supplement doses, which have not been characterized in long-term human trials. There is no established effective human supplement dose for raising NAD+ — the doses used in the landmark work were in cells and animals ² — so any "trigonelline 100 mg/300 mg for NAD+" label is extrapolated, not trial-derived.

As a supplement, trigonelline is sold as a dietary ingredient, not an FDA-approved treatment, so it isn't approved to treat or prevent any condition, and product quality and dose accuracy vary by manufacturer. Anyone who is pregnant or nursing, has a medical condition, or takes other medications — especially anything affecting blood sugar, given trigonelline's preclinical glucose effects — should clear it with a clinician first. This is consumer education, not medical advice.

The bottom line

Trigonelline is a real, peer-reviewed addition to NAD+ biology: a coffee- and fenugreek-derived alkaloid that the body can convert into NAD+, that is depleted in human sarcopenia, and that restored muscle function in aged mice and worms ². That's a strong mechanistic and preclinical story — and a legitimate reason it's the most interesting "next-gen" precursor to appear in years.

But strong preclinical data is not proof in people. There is no randomized human trial showing supplemental trigonelline raises NAD+ or improves muscle, energy, or aging in healthy adults, and the established precursors that do have such trials still struggle to convert raised NAD+ into felt benefit ³⁶. Treat trigonelline as a scientifically interesting compound to watch — not a validated upgrade over NMN or NR. For where the proven evidence actually stands, start with our NAD+ therapy evidence pillar, see how the precursors really perform in does NMN actually work? and NMN vs NR, and compare products and providers on our NAD+ rankings hub.